Since its creation, the Alexandre and Gaston Tytgat Foundation has honored researchers whose work has contributed significantly to progress in oncology. The Tytgat Prize is awarded every three years to recognize exceptional scientific achievement in Belgium, reflecting both the rigor of the research and its potential impact on our understanding and treatment of cancer.
Each laureate represents a unique contribution to the field: innovative ideas, groundbreaking methodologies, and discoveries that help shape the future of cancer research. Beyond the recognition itself, the Prize also seeks to encourage long-term scientific engagement and to provide visibility for the individuals and teams advancing knowledge in oncology.
This archive brings together all past laureates of the Tytgat Prize, offering a record of excellence across generations of Belgian research. It reflects the Foundation’s mission to reward talent, foster scientific creativity, and support the advancement of medical science for the benefit of society.
Plasma membrane receptors for cytokines in myeloproliferative disease
This research explores how plasma membrane cytokine receptors influence signaling pathways that drive abnormal blood cell proliferation in myeloproliferative diseases, providing insights into potential therapeutic targets.
How the tumor environment drives tumor metabolism and inversely
This research examined the interplay between tumor metabolism and its surrounding environment, revealing how each influences the other in cancer progression.
This research investigates the role of the tumor suppressor protein p53 in cancer development and explores innovative strategies to harness its biology for the design of more effective cancer therapies.
This research focuses on the development of advanced radiotherapy techniques, evolving from intensity-modulated radiation therapy (IMRT) to adaptive dose-painting, aiming to target tumors more precisely while minimizing damage to healthy tissue.
Prof. Pierre Roger, M.D., Ph.D. Carine Maenhaut, M.D., Ph.D.
ULB
Control of cell proliferation and gene expression in normal and tumor thyroid cells
This research examines the molecular mechanisms regulating cell growth and gene expression in thyroid cells, providing insight into how these processes differ between normal and cancerous states to better understand thyroid tumor development.
Prof. Jan Cools, M.D., Ph.D. Prof. Anne-Marie Hagemeyer Marynen, M.D., Ph.D. Prof. Peter Marynen, M.D., Ph.D.
KU Leuven
Novel (cryptic) chromosomal rearrangements of clinical relevance in malignancy
This research identifies and characterizes hidden chromosomal rearrangements that play a role in cancer, offering new insights into genetic mechanisms driving malignancies and their potential diagnostic and therapeutic implications.
Nouvelles implications des protéases stromales et de leurs inhibiteurs dans la progression tumorale
This research investigates the role of stromal proteases and their inhibitors in tumor progression, uncovering mechanisms by which the tumor microenvironment influences cancer growth and potential therapeutic targets.
Prof Pierre Coulie, M.D., Ph.D. Prof. Pierre Vanderbruggen, Ing., Ph.D. Prof. Benoit Vandeneynde, M.D., Ph.D.
UCL
Identification of tumor antigens potentially useful for specific immunotherapy of melanoma and other human tumors
This research focuses on identifying tumor-specific antigens that can be targeted for immunotherapy in melanoma and other cancers, aiming to develop more precise and effective treatments by leveraging the immune system.
Un seul et même gène à la base de l’origine de plusieurs tumeurs mésenchymateuses différentes
This research investigates how a single gene can underlie the development of multiple distinct mesenchymal tumors, providing insight into shared genetic mechanisms driving tumor formation and potential avenues for diagnosis and therapy.
This research summarizes ten years of studies on bovine leukemia, uncovering key viral and cellular mechanisms involved in disease progression and contributing to understanding viral-induced cancers in animals and humans.
Study of lysosomotropic chemotherapy—drugs accumulating in lysosomes—as a treatment approach in cancer, investigating cellular and biochemical effects.
The effect of heterologous antilymphocytic serum on the oncogenic activity of polyoma virus
Work exploring how antiserum can modulate the oncogenic (tumour-forming) properties of the polyoma virus, helping to understand virus-induced cancer mechanisms.
